查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870662

雙極性情感障礙治療市場按藥物類別、治療方法、疾病階段、通路、給藥途徑、患者年齡層和疾病類型分類－2025-2032年全球預測

Bipolar Disorder Therapeutics Market by Drug Class, Therapy Type, Disease Phase, Distribution Channel, Route Of Administration, Patient Age Group, Disorder Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，雙極性情感障礙治療市場將成長至 98 億美元，複合年成長率為 5.53%。

關鍵市場統計數據
基準年 2024 63.7億美元
預計年份：2025年 67.2億美元
預測年份 2032 98億美元
複合年成長率 (%) 5.53%

權威地審視雙極性情感障礙藥物治療領域的各個層面，整合臨床、商業性和政策觀點，為策略決策提供基礎。

雙極性情感障礙藥物治療處於精神病學、神經科學和衛生政策的複雜交會點，臨床異質性和不斷演變的治療模式要求我們獲得嚴謹且切實可行的見解。患者的病情發展軌跡各不相同，從急性躁鬱症或憂鬱症發作到需要長期維持治療不等。治療方法的選擇取決於療效、耐受性和合併症管理的差異。藥理學的最新進展，加上支付方期望的轉變和分銷管道的創新，正在改變臨床醫生、醫療系統和製藥廠商提供醫療服務的方式。

新興的藥物創新、支付方對實際結果的關注以及數位化醫療保健的結合，正在重新定義治療策略和競爭格局。

在科學、監管和醫療服務體系發展的共同推動下，雙極性情感障礙的治療格局正經歷快速變革時期。藥理學的進步拓展了治療選擇，使其不再局限於傳統的情緒穩定劑，而是發展出了具有更精細動態特徵的非典型抗精神病藥物和抗憂鬱症。同時，部分緩解和合併症等臨床現實，以及對聯合治療日益重視，正迫使臨床實踐轉向個人化和循序漸進的治療策略。

了解雙極性情感障礙藥物關稅政策的變化將如何影響供應鏈、臨床營運、定價動態和支付方決策。

關稅調整等政策措施透過多種實際途徑影響雙相情感障礙藥物生態系統，包括藥物取得、生產和商業計畫。對進口活性藥物原料藥、前驅物化學品或成品藥徵收關稅會增加上游採購成本，迫使製造商重新評估其供應商結構。為此，企業可能會尋求採購多元化、盡可能提高國內產能，或進行垂直整合以穩定供應並降低投入價格波動。

一個多維細分框架，將藥物類別、治療方法類型、疾病階段、通路、給藥途徑、患者年齡和疾病亞型與策略優先排序相結合。

細分市場提供了一種詳細的分析方法，有助於了解治療需求的促進因素，並確定優先的臨床和商業性路徑。依藥物類別進行分析，可以發現抗憂鬱症、非典型抗精神病藥物和情緒穩定劑之間的差異，每種藥物都具有獨特的安全性特徵和治療作用。抗憂鬱藥物又可細分為選擇性5-羥色胺和去甲腎上腺素再攝取抑制劑（SNRIs）、選擇性5-羥色胺再攝取抗憂鬱症（SSRIs）和三環類抗憂鬱劑（TCAs），它們在治療憂鬱症的效用方面各有不同。另一方面，非典型抗精神病藥物包括Aripiprazole、奧氮Olanzapine、Quetiapine平和Risperidone，它們經常被用於治療情緒障礙和精神病頻譜疾病。情緒穩定劑包括Carbamazepine、拉莫三嗪、鋰鹽和丙戊酸鹽，每種藥物都有已證實的調節情緒的療效，但不同的監測需求會影響其處方模式。

區域法規結構、支付方預期、製造地和數位化應用進展將如何塑造全球差異化的商業化策略

區域趨勢影響醫療服務的可近性、監管路徑和商業性執行，對產品組合規劃和打入市場策略具有重要意義。在美洲，多元化的支付方環境和強大的商業管道往往優先考慮可靠的衛生經濟學證據和結果研究，這些研究需證明能夠減少住院治療並改善病患功能。高度都市化的醫療系統正在加速臨床醫生整合遠端醫療和協作照護模式，並擴大專科醫師的執業範圍。

為什麼以證據生成、供應鏈韌性和整合式數位化合作為核心的企業策略將決定雙相情感障礙治療領域的競爭優勢

主要企業的措施體現了其應對臨床複雜性、成本壓力以及證明長期價值的策略性舉措。藥物研發公司持續投資於標靶臨床試驗和適應症擴展研究，以確定特定適應症並獲得有利的處方箋收錄。這些公司通常會將生命週期管理與患者援助計劃和藥物監測投資相結合，以維持患者依從性和安全性監測，尤其對於那些需要專業實驗室監管和劑量調整的藥物。

領導者應專注於實施的策略措施包括：確保供應韌性、產生長期證據以及將依從性解決方案融入治療價值提案。

在研發、商業化和市場准入等各個環節，產業領導者必須落實一系列切實可行的行動，將洞察轉化為可衡量的成果。應優先產生縱向的真實世界證據，將治療進展與住院率和功能恢復聯繫起來，從而使治療結果與支付方的優先事項保持一致，並加強報銷談判。同時，應透過採購多元化和合約保障措施建構供應鏈冗餘，以降低貿易政策變化帶來的風險，並確保依賴長期治療的患者能夠持續獲得治療。

透過嚴謹的證據分析，綜合運用臨床試驗、監管指引、藥物監測資料和供應鏈文件，為決策者提供具有實際操作意義的見解。

本執行摘要的研究途徑整合了同行評審的臨床文獻、監管指南、藥物監測報告和權威的公共分析，以建立強力的證據基礎。透過對隨機對照試驗、Meta分析和上市後監測數據進行批判性評價，並重點關注研究人群、終點指標和療效比較訊號，評估了臨床療效和安全性。監管機構和支付方的觀點則參考了已發表的檔案資料和報銷政策聲明，以確保其與實際決策標準相符。

對臨床、營運和社區需求的簡明總結表明，循證醫學、物資供應的韌性以及以患者為中心的醫療服務將如何決定未來治療的成功。

摘要，雙相情感障礙的治療正處於一個轉折點，臨床複雜性、支付方的嚴格審查以及供應鏈的實際情況相互交織，正在重塑治療方案的研發、實施和報銷方式。治療方法的差異化不僅取決於療效，還取決於已證實的真實世界有效性、在不同患者群體中的安全性，以及與依從性支持和數位化醫療解決方案的整合能力。諸如關稅調整等政策變化，凸顯了供應鏈韌性和與支付方積極合作以確保患者獲得治療的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合藥物治療和數位認知行為療法平台治療雙極性憂鬱症
  • 開發麩胺酸調節劑作為治療急性雙極性憂鬱症發作的快速療法
  • 長效注射抗精神病藥物製劑的進展可提高雙極性情感疾患患者的藥物順從性
  • 引入基於人工智慧的預測分析技術，用於早期檢測雙相情感障礙復發
  • 新興的生物標記指導的精準醫療方法可用於為雙相情感障礙患者個別化地制定情緒穩定劑治療方案
  • 利用智慧型手機監測應用程式獲取有關情緒變化和治療效果的真實世界證據

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按藥物類別分類的雙極性情感障礙治療市場

  • 抗憂鬱症
    • SNRIs（血清素-正腎上腺素再回收抑制劑）
    • 選擇性血清素再回收抑制劑（SSRIs）
    • 三環抗憂鬱藥物（TCAs）
  • 非典型抗精神病藥物
    • Aripiprazole
    • Olanzapine
    • Quetiapine
    • Risperidone
  • 情緒穩定劑
    • Carbamazepine
    • 拉莫三嗪
    • 鋰
    • 丙戊酸

9. 雙極性情感障礙治療市場（依治療方法）

  • 聯合治療
    • 非典型抗精神病藥和抗憂鬱症
    • 情緒穩定劑和抗憂鬱劑
    • 情緒穩定劑和非典型抗精神病藥物
  • 單藥治療

第10章：依疾病階段分類的雙極性情感疾患治療市場

  • 急性治療
  • 維持治療

第11章 雙極性情感障礙治療市場（按分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 雙極性情感疾患治療市場（依給藥途徑分類）

  • 注射
  • 口服

第13章 依患者年齡層分類的雙極性情感障礙治療市場

  • 成人版
  • 老年人
  • 兒童

第14章 雙極性情感疾患治療藥物市場（依疾病類型分類）

  • 雙極性情感障礙 I 型
  • 雙相II型
  • 環性心境障礙
  • 混合劇集
  • 快速循環型

第15章 雙極性情感障礙治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 雙極性情感疾患治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國雙極性情感障礙治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Otsuka Pharmaceutical Co., Ltd.
    • AstraZeneca PLC
    • AbbVie Inc.
    • Johnson & Johnson
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Novartis AG
    • H. Lundbeck A/S
Product Code: MRR-1A1A064C0280

The Bipolar Disorder Therapeutics Market is projected to grow by USD 9.80 billion at a CAGR of 5.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.37 billion
Estimated Year [2025] USD 6.72 billion
Forecast Year [2032] USD 9.80 billion
CAGR (%) 5.53%

An authoritative orientation to the multidimensional landscape of bipolar disorder therapeutics integrating clinical, commercial, and policy perspectives for strategic decision making

Bipolar disorder therapeutics occupy a complex intersection of psychiatry, neuroscience, and health policy where clinical heterogeneity and evolving treatment paradigms demand rigorous, actionable insights. Patients experience variable trajectories from acute manic or depressive episodes to long-term maintenance needs, and therapeutic selection hinges on differential efficacy, tolerability, and comorbidity management. Recent advances in pharmacology, coupled with shifting payer expectations and distribution innovations, have transformed how clinicians, health systems, and manufacturers approach care delivery.

This executive summary synthesizes clinical, commercial, and regulatory dimensions relevant to decision-makers engaged in bipolar disorder therapeutics. It outlines transformative shifts reshaping the landscape, evaluates the implications of tariff policy on supply chains and access, unpacks segmentation drivers that underlie therapy choice, and surfaces regional dynamics that influence commercial strategies. The narrative emphasizes practical implications for development, commercialization, and policy engagement while identifying levers that industry leaders can use to enhance patient outcomes and sustain competitive advantage.

Throughout, the analysis privileges evidence-based commentary and operationally relevant recommendations, enabling clinical development teams, market access professionals, and commercial leadership to translate findings into prioritized actions across research, manufacturing, and go-to-market planning.

How emergent pharmacologic innovations combined with payer emphasis on real-world outcomes and digital-enabled care are redefining therapeutic strategies and competitive dynamics

The therapeutic landscape for bipolar disorder is undergoing a period of accelerated transformation driven by converging scientific, regulatory, and delivery-system developments. Advances in pharmacology have broadened the palette of treatment options beyond classical mood stabilizers into refined atypical antipsychotics and antidepressant classes with more nuanced pharmacodynamic profiles. Concurrently, growing attention to combination regimens acknowledges the clinical reality of partial responses and comorbidity, prompting clinical practice to adapt toward personalized, sequence-aware strategies.

At the regulatory and payer interface, heightened emphasis on real-world effectiveness and tolerability has shifted reimbursement conversations from narrow efficacy endpoints toward longitudinal outcomes that encompass adherence, hospitalization avoidance, and functional recovery. Technology-enabled care pathways, including telepsychiatry and digital adherence tools, are increasing reach and creating new channels for longitudinal monitoring and early intervention. Manufacturing innovation and active-ingredient sourcing are evolving alongside these clinical shifts, with branded players pursuing lifecycle strategies while generic manufacturers focus on improving access and affordability.

These combined forces are reshaping clinical pathways and competitive dynamics, creating new opportunities for differentiated therapeutic positioning, evidence generation that aligns with payer metrics, and collaborations that integrate pharmacotherapy with digital and behavioral modalities for more holistic patient care.

Understanding how tariff policy shifts can reverberate through supply chains, clinical operations, pricing dynamics, and payer decision making in bipolar disorder therapeutics

Policy actions such as tariff adjustments influence the bipolar disorder therapeutics ecosystem through several practical channels that affect access, manufacturing, and commercial planning. Tariffs imposed on imported active pharmaceutical ingredients, precursor chemicals, or finished formulations can amplify upstream procurement costs and compel manufacturers to reassess supplier footprints. In response, firms may diversify sourcing, increase domestic production capacity where feasible, or pursue vertical integration to stabilize supplies and control input pricing volatility.

Clinical operations and trial execution can be indirectly affected when changes in trade policy disrupt timelines for component availability or laboratory supplies. Sponsors conducting multi-site clinical programs should therefore monitor procurement lead times and establish contingency inventories to mitigate interruption risk. From a payer and provider perspective, any tariff-induced cost pressure that increases list prices or short-term supply constraints can provoke formulary re-evaluations and substitution toward therapeutically equivalent alternatives where clinically appropriate.

Regulatory mechanisms and public-private coordination can blunt negative impacts; for example, targeted exemptions for critical pharma inputs or expedited approvals for alternate suppliers reduce downstream disruption. Strategic planning at the corporate level should integrate scenario-based supply-chain risk assessments, contractual safeguards with suppliers, and proactive payer engagement to demonstrate value and manage potential access constraints arising from tariff-driven cost dynamics.

A multidimensional segmentation framework that aligns drug class, therapy type, disease phase, distribution channel, administration route, patient age, and disorder subtype to strategic prioritization

Segmentation offers a granular lens for understanding therapeutic demand drivers and identifying high-priority clinical and commercial pathways. When analyzed by drug class, differences between antidepressants, atypical antipsychotics, and mood stabilizers reveal distinct safety profiles and therapeutic roles; antidepressants subdivide into SNRIs, SSRIs, and TCAs with varying utility in depressive polarity, while atypical antipsychotics include agents such as aripiprazole, olanzapine, quetiapine, and risperidone that are frequently repurposed across mood and psychotic-spectrum presentations. Mood stabilizers encompass carbamazepine, lamotrigine, lithium, and valproate, each with established evidence for mood control and divergent monitoring requirements that influence prescribing patterns.

Therapy-type segmentation highlights the differential uptake of monotherapy versus combination approaches, with combination regimens like atypical antipsychotic and antidepressant, mood stabilizer and antidepressant, or mood stabilizer and atypical antipsychotic employed to address partial response or comorbid symptoms. Disease-phase segmentation separates acute treatment from maintenance therapy, underscoring the need for short-term symptom control versus long-term relapse prevention strategies and differing adherence support mechanisms.

Distribution-channel distinctions across hospital pharmacy, online pharmacy, and retail pharmacy affect patient access, continuity of care, and the feasibility of complex regimens. Route-of-administration segmentation, whether injectable or oral, alters adherence dynamics and care setting requirements. Patient age group segmentation into adult, geriatric, and pediatric cohorts demands tailored safety and dosing considerations, while disorder-type distinctions between bipolar I, bipolar II, cyclothymia, mixed episode, and rapid cycling drive differing clinical priorities and therapeutic responses. Integrating these segmentation axes provides a multidimensional framework for prioritizing development programs, market access dossiers, and tailored clinical support initiatives.

How divergent regional regulatory frameworks, payer expectations, manufacturing footprints, and digital adoption trajectories shape differentiated commercialization strategies globally

Regional dynamics shape access, regulatory pathways, and commercial execution in ways that are material for portfolio planning and market-entry strategy. In the Americas, diversified payer landscapes and strong commercial channels often prioritize robust health-economic evidence and outcomes studies that demonstrate hospitalization avoidance and functional gains; clinicians in heavily urbanized health systems increasingly integrate telemedicine and collaborative care models to extend specialist reach.

Across Europe, Middle East & Africa, heterogeneous regulatory environments and variable reimbursement models require adaptive strategies that combine centralized evidence packages with country-specific value dossiers and local real-world evidence generation. Supply-chain resilience and pricing negotiations are pivotal in regions where procurement mechanisms and public-sector contracting influence the availability of branded and generic alternatives. In Asia-Pacific, rapid uptake of digital health platforms and growing domestic manufacturing capabilities are notable. Policymaker emphasis on expanding access, combined with significant private-sector innovation in telehealth and e-pharmacy channels, creates both opportunity and competitive pressure for entrants to localize strategies and partnerships.

Collectively, these regional contrasts necessitate differentiated commercialization blueprints that align evidence generation, manufacturing footprint, and distribution partnerships with local payer expectations and patient access pathways to maximize therapeutic reach and sustainability.

Why company strategies centered on evidence generation, supply resilience, and integrated digital partnerships are defining competitive advantage in bipolar therapeutics

Key company behaviors reflect strategic responses to clinical complexity, cost pressures, and the imperative to demonstrate longitudinal value. Innovator companies continue to invest in targeted clinical trials and label-expansion studies that seek to delineate niche indications and secure favorable formulary positioning. These sponsors often couple lifecycle management with patient-support programs and pharmacovigilance investments to sustain adherence and safety monitoring, particularly for agents requiring specialized laboratory surveillance or titration.

Generic and specialty manufacturers focus on supply reliability, cost-efficient production, and incremental product enhancements such as novel formulations or adherence aids to maintain competitiveness in crowded therapeutic classes. Cross-sector collaborations between pharmaceutical firms and digital health companies are increasingly common, as firms pursue adjunctive tools that can capture real-world outcomes, promote adherence, and create differentiation beyond the molecule.

Mergers, acquisitions, and strategic alliances remain pragmatic levers to accelerate pipeline diversification, obtain manufacturing scale, or gain market access in specific geographies. Companies that deploy integrated evidence strategies-combining randomized data, real-world outcomes, and health-economic models-tend to navigate formulary and procurement negotiations more effectively, enabling smoother adoption across both acute and maintenance treatment settings.

Actionable strategic priorities for leaders to secure supply resilience, generate longitudinal evidence, and integrate adherence-enabling solutions into therapeutic value propositions

Industry leaders must operationalize a set of pragmatic actions that translate insights into measurable outcomes across development, commercialization, and access functions. Prioritize the generation of longitudinal real-world evidence that maps treatment sequences to hospitalization rates and functional recovery, thereby aligning outcomes with payer priorities and enhancing reimbursement discussions. Concurrently, build supply-chain redundancy through diversified sourcing or contractual safeguards to mitigate risks from trade policy shifts and ensure uninterrupted access for patients reliant on long-term therapies.

Invest in differentiated value propositions that combine pharmacologic efficacy with adherence-enabling technologies and structured patient support programs; these integrated solutions improve clinical outcomes and create persuasive value narratives for payers and health systems. Tailor regional strategies by harmonizing core evidence packages with local-value dossiers and partner with regional distributors to navigate heterogeneous regulatory and procurement landscapes.

Finally, embed scenario-based planning into clinical development and commercial playbooks to respond quickly to policy changes, competitive launches, and evolving clinical guidelines. Cross-functional coordination between clinical research, market access, manufacturing, and commercial teams is essential to convert strategic intent into scalable programs that sustain patient access and commercial performance.

A rigorous evidence synthesis that triangulates clinical trials, regulatory guidance, pharmacovigilance data, and supply-chain documentation to produce operationally relevant insights for decision makers

The research approach underpinning this executive summary synthesizes peer-reviewed clinical literature, regulatory guidances, pharmacovigilance reports, and authoritative public policy analyses to construct a robust evidence base. Clinical efficacy and safety profiles were evaluated through critical appraisal of randomized controlled trials, meta-analyses, and post-marketing surveillance data with attention to study populations, endpoints, and comparative effectiveness signals. Regulatory and payer perspectives were contextualized using public docket materials and reimbursement policy statements to ensure alignment with real-world decision criteria.

Supply-chain and tariff impact analysis integrated trade policy documentation, procurement process insights, and manufacturer disclosures to map potential operational implications. Segmentation and regional analyses drew on therapeutic usage patterns, care pathway descriptions, and distribution-channel trends to create actionable frameworks for prioritizing commercial investments. Triangulation across data sources and expert validation steps were applied to reduce bias and enhance the interpretability of findings for senior decision-makers.

Limitations of the methodology include variability in reporting standards across jurisdictions and the evolving nature of clinical evidence; however, the approach emphasizes transparent sourcing and conservative interpretation to deliver insights that are operationally relevant and resilient under multiple conditions.

A concise synthesis of clinical, operational, and regional imperatives indicating how evidence, supply resilience, and patient-centered delivery will determine future therapeutic success

In sum, bipolar disorder therapeutics are at an inflection point where clinical complexity, payer scrutiny, and supply-chain realities converge to reshape how treatments are developed, delivered, and reimbursed. Therapeutic differentiation will depend not only on efficacy but also on demonstrated real-world impact, safety in diverse patient cohorts, and the ability to integrate with adherence and digital-care solutions. Policy shifts such as tariff changes amplify the importance of supply resilience and proactive payer engagement to safeguard access.

Segment-aware strategies that account for drug-class nuances, therapy combinations, disease phase needs, distribution models, routes of administration, age-specific considerations, and disorder subtypes are vital for precise portfolio prioritization. Regional particularities further necessitate tailored evidence packages and localized partnerships to navigate regulatory and procurement complexities. Ultimately, companies that combine rigorous evidence generation with operational resilience and patient-centered delivery models are best positioned to improve outcomes and sustain commercial viability.

This executive summary offers a strategic foundation; translating these insights into concrete actions requires cross-functional commitment to evidence planning, supply-chain optimization, and adaptive commercial execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of digital cognitive behavioral therapy platforms with pharmacological management for bipolar depression
  • 5.2. Development of glutamatergic modulators as rapid acting treatments for acute bipolar depressive episodes
  • 5.3. Advances in long acting injectable antipsychotic formulations to improve adherence in bipolar disorder patients
  • 5.4. Implementation of artificial intelligence based predictive analytics for early detection of bipolar disorder relapse
  • 5.5. Emerging biomarker guided precision medicine approaches to tailor mood stabilizer therapy in bipolar patients
  • 5.6. Utilization of smartphone monitoring apps for real world evidence on mood variability and treatment outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bipolar Disorder Therapeutics Market, by Drug Class

  • 8.1. Antidepressants
    • 8.1.1. SNRIs
    • 8.1.2. SSRIs
    • 8.1.3. TCAs
  • 8.2. Atypical Antipsychotics
    • 8.2.1. Aripiprazole
    • 8.2.2. Olanzapine
    • 8.2.3. Quetiapine
    • 8.2.4. Risperidone
  • 8.3. Mood Stabilizers
    • 8.3.1. Carbamazepine
    • 8.3.2. Lamotrigine
    • 8.3.3. Lithium
    • 8.3.4. Valproate

9. Bipolar Disorder Therapeutics Market, by Therapy Type

  • 9.1. Combination Therapy
    • 9.1.1. Atypical Antipsychotic And Antidepressant
    • 9.1.2. Mood Stabilizer And Antidepressant
    • 9.1.3. Mood Stabilizer And Atypical Antipsychotic
  • 9.2. Monotherapy

10. Bipolar Disorder Therapeutics Market, by Disease Phase

  • 10.1. Acute Treatment
  • 10.2. Maintenance Therapy

11. Bipolar Disorder Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Bipolar Disorder Therapeutics Market, by Route Of Administration

  • 12.1. Injectable
  • 12.2. Oral

13. Bipolar Disorder Therapeutics Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. Bipolar Disorder Therapeutics Market, by Disorder Type

  • 14.1. Bipolar I
  • 14.2. Bipolar II
  • 14.3. Cyclothymia
  • 14.4. Mixed Episode
  • 14.5. Rapid Cycling

15. Bipolar Disorder Therapeutics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Bipolar Disorder Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Bipolar Disorder Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Otsuka Pharmaceutical Co., Ltd.
    • 18.3.2. AstraZeneca PLC
    • 18.3.3. AbbVie Inc.
    • 18.3.4. Johnson & Johnson
    • 18.3.5. Sumitomo Dainippon Pharma Co., Ltd.
    • 18.3.6. Eli Lilly and Company
    • 18.3.7. GlaxoSmithKline plc
    • 18.3.8. Merck & Co., Inc.
    • 18.3.9. Novartis AG
    • 18.3.10. H. Lundbeck A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BIPOLAR DISORDER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BIPOLAR DISORDER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIPOLAR DISORDER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SNRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SSRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TCAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTIC AND ANTIDEPRESSANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ANTIDEPRESSANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZER AND ATYPICAL ANTIPSYCHOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY BIPOLAR II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CYCLOTHYMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MIXED EPISODE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RAPID CYCLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISEASE PHASE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DISORDER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2